CoSara Diagnostics has become the first Indian company to receive a licence from the Central Drugs Standard Control Organisation (CDSCO) to manufacture Covid-19 diagnostic test kits, Business Standard reported on Sunday.
The company plans to send sample batches to National Institute of Virology, Pune, for validation, after which it would apply for a manufacturing licence with the government.
"We are not giving the price right now because it is still dependent on various factors," said CEO Mohal Sarabhai, adding that "it will be lower than whatever the imported prices are right now."
"Our molecular diagnostics platform using the polymerase chain reaction technology can deliver results in two and a half hours. We already have manufacturing licence for molecular diagnostics to cover diseases like tuberculosis, hepatitis B, hepatitis C, human papillomavirus and malaria which are being manufactured from the Vadodara plant," he added.
Sarabhai said the company is ready to commence manufacturing of the diagnostic tests in a week or two.
"We have already placed orders for the raw materials including primer and probes right now from approved source in the US," he added.